Literature DB >> 16167015

Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies.

James L M Ferrara1, Gregory Yanik.   

Abstract

Acute graft versus host disease (GVHD) remains the greatest complication of allogeneic bone marrow transplantation and a major cause of morbidity and mortality. This article summarizes the risk factors and prevention strategies for acute GVHD by considering them within the context of disease pathophysiology. Acute GVHD can be considered a 3-step process: 1) damage from chemotherapy/radiotherapy; 2) host antigen-presenting cell activation and amplification of donor T cells; and 3) target cell apoptosis via cellular and inflammatory mediators. This conceptual framework helps to explain the effectiveness of current prevention strategies and points to areas where new drugs and approaches may be of clinical benefit.

Entities:  

Mesh:

Year:  2005        PMID: 16167015

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  11 in total

1.  Deletion of Fanca or Fancd2 dysregulates Treg in mice.

Authors:  Wei Du; Ozlem Erden; Andrew Wilson; Jared M Sipple; Jonathan Schick; Parinda Mehta; Kasiani C Myers; Kris A Steinbrecher; Stella M Davies; Qishen Pang
Journal:  Blood       Date:  2014-02-05       Impact factor: 22.113

2.  Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation.

Authors:  Mathias M Hauri-Hohl; Marcel P Keller; Jason Gill; Katrin Hafen; Esther Pachlatko; Thomas Boulay; Annick Peter; Georg A Holländer; Werner Krenger
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

3.  CXCL10 can be detected non-invasively from the skin of children with acute skin GvHD.

Authors:  P Khandelwal; K Smiley; A M Fieno; R A Grant; S M Davies
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

4.  Investigation of functional IL-10 gene polymorphism and IL-10 levels in acute graft-versus-host disease.

Authors:  Renata Gonçalves Resende; Jeane de Fátima Correia-Silva; Telma Cristina Arão; Tarcília Aparecida Silva; Mauro Henrique Nogueira Guimarães Abreu; Henrique Bittencourt; Ricardo Santiago Gomez
Journal:  J Clin Immunol       Date:  2010-03-02       Impact factor: 8.317

5.  IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease.

Authors:  David Polchert; Justin Sobinsky; Gw Douglas; Martha Kidd; Ada Moadsiri; Eduardo Reina; Kristyn Genrich; Swati Mehrotra; Suman Setty; Brett Smith; Amelia Bartholomew
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

Review 6.  Antibody- and aptamer-strategies for GvHD prevention.

Authors:  Christopher Oelkrug; Ulrich Sack; Andreas Boldt; Isis C Nascimento; Henning Ulrich; Stephan Fricke
Journal:  J Cell Mol Med       Date:  2014-10-29       Impact factor: 5.310

Review 7.  Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies.

Authors:  Nancy Y Villa; Masmudur M Rahman; Grant McFadden; Christopher R Cogle
Journal:  Viruses       Date:  2016-03-22       Impact factor: 5.048

Review 8.  Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs.

Authors:  Vanessa Innao; Vincenzo Rizzo; Andrea Gaetano Allegra; Caterina Musolino; Alessandro Allegra
Journal:  Curr Oncol       Date:  2020-12-25       Impact factor: 3.677

Review 9.  Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies.

Authors:  Sina Naserian; Mathieu Leclerc; Sara Shamdani; Georges Uzan
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

Review 10.  Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease.

Authors:  Nancy Y Villa; Grant McFadden
Journal:  Curr Pathobiol Rep       Date:  2018-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.